Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)-Reference-Cited by-同舟云学术

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

Published:2018-10-09 Issue:551 Volume:11 Page:
ISSN:1945-0877
Container-title:Science Signaling
language:en
Short-container-title:Sci. Signal.

Author:

Cocco Emiliano¹,Javier Carmona F.¹,Razavi Pedram¹²,Won Helen H.¹³,Cai Yanyan¹³^ORCID,Rossi Valentina⁴^ORCID,Chan Carmen¹^ORCID,Cownie James¹,Soong Joanne¹^ORCID,Toska Eneda¹^ORCID,Shifman Sophie G.¹^ORCID,Sarotto Ivana⁵^ORCID,Savas Peter⁶^ORCID,Wick Michael J.⁷^ORCID,Papadopoulos Kyriakos P.⁷^ORCID,Moriarty Alyssa⁷,Cutler Richard E.⁸,Avogadri-Connors Francesca⁸^ORCID,Lalani Alshad S.⁸,Bryce Richard P.⁸,Chandarlapaty Sarat¹²^ORCID,Hyman David M.²^ORCID,Solit David B.¹²⁹^ORCID,Boni Valentina¹⁰^ORCID,Loi Sherene⁶^ORCID,Baselga José¹²^ORCID,Berger Michael F.¹³^ORCID,Montemurro Filippo⁴^ORCID,Scaltriti Maurizio¹³^ORCID

Affiliation:

1. Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

2. Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

3. Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

4. Unit of Investigative Clinical Oncology (INCO), Candiolo Cancer Institute, FPO-IRCCS, Str. Provinciale 142, 10060 Candiolo, Italy.

5. Unit of Surgical Pathology, Fondazione del Piemonte per l’Oncologia, Candiolo Cancer Institute, FPO-IRCCS, Str. Provinciale 142, 10060 Candiolo, Italy.

6. Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC 3000, Australia.

7. START, 4383 Medical Dr, San Antonio, TX 78229, USA.

8. Puma Biotechnology Inc., 10880 Wilshire Blvd, Los Angeles, CA 90024, USA.

9. Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

10. START Madrid, Centro Integral Oncológico Clara Campal, Hospital Universitario Madrid Sanchinarro, Calle de Oña 10, 28050 Madrid, Spain.

Abstract

Metastatic breast cancer patients with coexistent HER2 mutation and amplification respond to neratinib.

Funder

NIH Office of the Director

Breast Cancer Research Foundation

Geoffrey Beene Cancer Research Center

Ministero della Salute